Artemisinin Combination Therapy Market Size and Competitive Analysis till 2031

MARKET INTRODUCTION

Artemisinin combination therapy used to treatment of malaria disease. Malaria is a serious, life threatening disease spread by mosquitoes & causes by a parasite which mainly destroy red blood cell in the body. The artemiisinin combination therapy work with partner drug. The artemisinin compound play important role in reduction of no. of parasites during the 1st three days of treatment (reduction of parasite biomass) and the role of partner drug is to eliminate the remaining parasite. The artemisinin is a drug derived from the Asian plant Artemisia annua.

MARKET DYNAMICS

The artemisinin combination therapy market is expected to grow during the forecast period owing to the key driving factors such as rising demand for artemisinin combination therapy, increasing pollution related problems, the various government initiatives for malaria disease awareness. In addition, various players in the emerging market have strong pipeline product and high potential which are anticipated to create several growth opportunities for the market during the forecast period.

MARKET SCOPE

The "Global Artemisinin Combination Therapy Market Analysis to 2031" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of artemisinin combination therapy with detailed market segmentation by type, distribution channel and geography. The global artemisinin combination therapy market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading the artemisinin combination therapy market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global artemisinin combination therapy market is segmented on the basis of type and distribution channels. Based on type, the market is segmented as artemether-lumefantrine, Artesunate-amodiaquine, dihydroartemisinin-piperaquine, artesunate-mefloquine, artesunate-sulfadoxine-pyrimethamine and pyronaridine-artesunate. On the basis of distribution channel the global artemisinin combination therapy market is classify into retail pharmacy, hospitals and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global artemisinin combination therapy market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The artemisinin combination therapy market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting artemisinin combination therapy market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the artemisinin combination therapy market in these regions.

MARKET PLAYERS

The reports cover key developments in the artemisinin combination therapy market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from artemisinin combination therapy market are anticipated to lucrative growth opportunities in the future with the rising demand for artemisinin combination therapy market in the global market. Below mentioned is the list of few companies engaged in the artemisinin combination therapy market.

The report also includes the profiles of key artemisinin combination therapy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

• Hovid-Integrated Global Pharmaceutical Partner
• Ipca Laboratories Ltd
• Aspen Holdings
• AJANTA PHARMA
• Novartis AG
• Sanofi
• Cipla Inc
• KPC Pharmaceuticals
• Mylan N.V
• Calyx Chemicals and Pharmaceuticals Limited

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Artemisinin Combination Therapy Report Scope